Literature DB >> 7504341

The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts.

P K Koskinen1.   

Abstract

Previous studies have suggested that during acute heart allograft rejection the expression of vascular adhesion molecules is induced. This study was designated to investigate the expression of three adhesion molecules ICAM-1 (CD 54), VCAM-1, and ELAM-1, and the counter-ligands LFA-1 (CD 18), Mac-1 (CD 11b/CD 18), and VLA-4 (CD 49d) in frozen sections of endomyocardial biopsies (EMB) of heart allografts in relation to onset of CMV infection recorded as CMV antigenemia. The expression of MHC class II antigens and interleukin-2-receptor was also analyzed. A total of 105 EMBs and 840 immunoperoxidase stainings obtained from 21 heart transplant recipients were analyzed. EMBs from 9 patients with CMV infections, 5 patients with rejections, and 7 patients with a noncomplicated postoperative course were included. An induction of VCAM-1 occurred in relation to onset of CMV antigenemia. The expression of VCAM-1 remained elevated for several weeks declining slowly to control levels. Associated with CMV infection, capillary expression of VCAM-1 (P < 0.001) and ELAM-1 (P < 0.03) was significantly induced when compared with control biopsies. ICAM-1 expression was always seen in capillaries--and also in controls. A striking difference in the expression of VCAM-1 during rejection and CMV infection was observed: in most rejecting biopsies only a few capillaries stained faintly for VCAM-1, whereas during CMV infection multifocal intense staining was found (P < 0.0001). Induction of ELAM-1 was associated with acute rejections. In general, the expression of ligand counterparts was at a higher level during rejection compared with CMV infection. However, a short-term induction of VLA-4 occurred after the onset of CMV antigenemia (N.S.). Thus, the VCAM-1/VLA-4 ligand pair may play an important role in adhesion of lymphocytes and monocytes to capillary endothelium during active CMV infection and may also contribute to the pathogenesis of increased vasculopathic changes reported in CMV-infected heart transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504341     DOI: 10.1097/00007890-199311000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent.

Authors:  C Söderberg-Nauclér; D N Streblow; K N Fish; J Allan-Yorke; P P Smith; J A Nelson
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection.

Authors:  I Nordøy; F Müller; K P Nordal; H Rollag; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

4.  Triple drug immunosuppression significantly reduces immune activation and allograft arteriosclerosis in cytomegalovirus-infected rat aortic allografts and induces early latency of viral infection.

Authors:  K B Lemström; J H Bruning; C A Bruggeman; I T Lautenschlager; P J Häyry
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

5.  Human cytomegalovirus causes endothelial injury through the ataxia telangiectasia mutant and p53 DNA damage signaling pathways.

Authors:  Y H Shen; B Utama; J Wang; M Raveendran; D Senthil; W J Waldman; J D Belcher; G Vercellotti; D Martin; B M Mitchelle; X L Wang
Journal:  Circ Res       Date:  2004-04-22       Impact factor: 17.367

Review 6.  Endothelial dysfunction and cardiac allograft vasculopathy.

Authors:  Monica Colvin-Adams; Nonyelum Harcourt; Daniel Duprez
Journal:  J Cardiovasc Transl Res       Date:  2012-11-08       Impact factor: 4.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.